Dainippon and Takeda Form Alliance in a New Anti-Diabetic Agent
OSAKA, JAPAN --- Dainippon Pharmaceutical Co., Ltd. ("Dainippon", President: Kenjiro Miyatake) and Takeda Chemical Industries, Ltd. ("Takeda", President: Kunio Takeda) jointly announced today that on September 29, 1999, they signed a preliminary agreement that Takeda will receive the development and marketing rights of Dainippon's new anti-diabetic agent, AJ-9677 (Takeda's development code: TAK-677), in the world except Japan, China, Taiwan and South Korea.
AJ-9677, created by Dainippon, is a β3-adrenaline receptor agonist which improves both lipid and glycemic metabolism by reducing insulin resistance and is accordingly expected to be a new class of anti-diabetic agent for type 2 diabetes. Moreover, since this compound has the function of promoting energy consumption, it has a potential to be developed as an anti-obesity drug.
Dainippon believes that AJ-9677, which is now under phase I clinical studies in Japan, is a strategically important product for their pharmaceutical Business.
Takeda evaluates that the compound will be beneficial to expand their anti-diabetic product line for their global business activities, and plans to initiate phase I clinical studies for TAK-677 in the United States soon.
This alliance will lead to simultaneously developing AJ-9677 (TAK-677) in Japan, the U.S. and European countries. Consequently, Dainippon and Takeda believe that they will be able to contribute to the treatment of type 2 diabetes in the world.